20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
AstraZeneca along with its global biologics R&D research arm MedImmune announced that their immune-oncology combo-treatment for non-small cell lung cancer, or NSCLC, did not meet the primary endpoint in a late-stage study.
The trial dubbed MYSTIC evaluated Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumba for treating previously untreated patients with metastatic Stage-1V, first-line NSCLC. The combo was compared with the platinum-based standard of-care chemotherapy.
The companies said the combo did not meet the primary end point of improving progression free survival, or PFS, compared to chemotherapy in patients whose tumors express PD-L1 on 25 percent or more of their cancer cells.
See also: Analyst Prescribes Neutral Rating For Pfizer SharesThe failed study is a major setback for the company's efforts to pose a potent threat to established players in the NSCLC space such as Merck & Co., Inc. (NYSE:MRK) and Bristol-Myers Squibb Co (NYSE:BMY).
"As a secondary endpoint, although not formally tested, Imfinzi monotherapy would not have met a pre-specified threshold of PFS benefit over SoC in this disease setting," the companies added.
Meanwhile, AstraZeneca said the trial will continue to assess two additional primary endpoints of overall survival for Imfinzi monotherapy as well as the combo.
Final overall survival data is expected during the first half of 2018.
AstraZeneca also stated that it had recently received accelerated approval for Imfinzi in previously-treated patients with locally advanced or metastatic urothelial carcinoma.
Meanwhile, separately, AstraZeneca announced that a late-stage study dubbed FLAURA that evaluated Tagrisso compared to the current first-line standard of care treatment, namely erlotinib or gefitinib, showed statistically significant and clinically-meaningful PFS benefit. The treatment option was evaluated in previously-untreated patients with locally-advanced or metastatic epidermal growth factor receptor mutation-positive, or EGFRm, NSCLC.
AstraZeneca also announced financial results for the first-half, with second quarter earnings and revenues topping expectations. This is despite the company's drug sales falling, as it is yet to recover from the loss of patent for its blockbuster cholesterol drug Crestor.
At time of publication, shares of AstraZeneca were down 15.41 percent at $28.71 in Thursday's pre-market session.
______Image Credit: By Bjoertvedt - Own work, CC BY-SA 4.0, via Wikimedia Commons20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!